Introduction fibrosis is reported and cirrhosis seems exceptional [3] . Methotrexate (MTX ), a folic antagonist, is the most However, psoriastic patients treated with MTX may widely used slow-acting anti-rheumatic agent in the develop significant liver disease, including cirrhosis, treatment of rheumatoid arthritis (RA), with the best which may not be predicted by liver enzymes [2] . These efficacy/toxicity ratio [1] . The major concern of its longpatients are monitored according to dermatologists' term use is hepatotoxicity. Histological abnormalities in guidelines for MTX with routine liver biopsies [4] . patients treated with MTX include non-specific histoIn RA patients, MTX monitoring relies on ACR logical features such as fatty change, focal liver cell (American College of Rheumatology) recommendations necrosis, portal tract inflammation, nuclear pleiomorph- [5] for liver biopsy, using Roenigk histological grading ism, and specific lesions such as fibrosis with collagen [6 ] , and serum transaminases [aspartate aminotransferaccumulation, particularly in the perisinusoidal space ase (AST ) and alanine aminotransferase (ALT )]. [2] . Depending on the study, the reported overall risk However, liver enzymes are not always correlated with of fibrosis ranges from 3 to 52% [2] . In RA patients histological data [7] and the Roenigk score was found to be insensitive for detection of small changes in the degree of fibrosis [8] . In France, a new semi-quantitative and viral hepatitis [9] . It analyses four sites of fibrosis: by the same liver pathologists [9] . The inter-observer correlation was 0. The PS and PT were the most commonly altered areas: 1.35 ± 0.63 (0-2) for PS and 1.16 ± 0.65 (0-2) for PT.
Liver biopsy assessment
AST, ALT and daily dose of prednisone were not Two semi-quantitative scoring systems were performed correlated with any of the two scores. blindly on the specimens by two liver pathologists. When their Roenigk scores differed, the pathologists conferred
Comparison of the three groups of patients Patient characteristics. The 38 patients of group 1 and then gave the mean of both measures. The interobserver reproducibility for the SSS is not stated here (pre-treatment group) were significantly (P < 0.05) older and had more active RA than patients of the other because it has been determined in chronic viral hepatitis groups ( Table 1) . They differed significantly (P < 0.05) respectively. No statistically significant difference between the three groups was found. A mild fibrosis from other groups by a longer duration of morning stiffness, a higher Lee and Ritchie index, a higher ESR (grade IIIA) was observed in 39.5% (15/38), 40% (4/10) and 23.1% (6/26) of patients in groups 1, 2 and 3, and a higher CRP level.
AST and ALT were higher in the third group than in respectively ( Fig. 2) . Mean SSS was 5.1 ± 3.2, 4.2 ± 1.6 and 4.2 ± 2.2 in the first one (P = 0.0002 and P = 0.001, respectively), but their mean values remained within the normal range. groups 1, 2 and 3, respectively. No statistically significant difference between groups was found. A mild fibrosis Albuminaemia was significantly (P = 0.03) lower in group 1 than in group 3.
(SSS from 2 to 4) was seen in 50% (19/38), 40% (4/10) and 50% (13/26) of patients in groups 1, 2 and 3 The number of previous DMARDs and NSAIDs, cortisone intake, and the rheumatoid factor level were respectively. A moderate fibrosis (5-10) was seen in 36.8% (14/38), 60% (6/10) and 42.3% (11/26) of patients similar in the three groups.
Histological scores The Roenigk mean score was in groups 1, 2 and 3, respectively. Severe fibrosis (11-15) was only found in three patients of group 1 ( Fig. 2 ). 1.8 ± 0.9, 2.3 ± 0.8 and 1.6 ± 0.9 in groups 1, 2 and 3, The width of septa ( WS) was slightly improved rosis, cirrhosis and only portal fibrosis while the SSS quantifies fibrosis at different localizations and ranges (0.1 < P < 0.2) after 2 g of MTX using the ANOVA: 0.81 ± 1.08 before MTX vs 0.36 ± 0.57 after 2 g of largely from 0 to 35. The relative sensitivity to change of the two scores has not been evaluated since they did MTX. The PS and PT were the most commonly altered areas: 1.35 ± 0.63 (0-2) for PS and 1.16 ± 0.65 (0-2) not differ in the three groups of patients. Nevertheless, SSS might be recommended for the evaluation of hepatic for PT before MTX was not significantly different from 1.24 ± 0.66 (PS) and 1.04 ± 0.61 (PT ) after 2 g. There fibrosis in RA patients treated with MTX. Hepatic histological alterations were frequently was no significant difference between the three groups for CLV and NS.
observed in patients who were biopsied before MTX initiation. The findings were similar to previously The Roenigk score and the SSS did not vary significantly in the 11 patients with paired biopsies. In this reported observations [10, 11] . Such lesions are generally attributed to RA itself and also to the intake of NSAIDs, latter group, the Roenigk mean score was 1 ± 0 and 1.12 ± 0.64, and mean SSS was 5.1 ± 3.2 and 4.5 ± 2.6 analgesics, corticosteroids and DMARDs, which may induce fatty change, inflammation, necrosis or fibrosis before and after MTX, respectively. [12] . The alterations were only graded IIIA with the Roenigk score. Hepatic fibrosis was routinely detected Discussion by SSS in such specimens but was rarely graded as severe, in agreement with the study of Ruderman et al. The SSS of Chevalier et al. [9] was designed for the staging and follow-up of hepatic fibrosis in patients with [11] . Hepatic fibrosis is the main concern of long-term chronic liver diseases. SSS was also made to tackle the heterogeneity in the distribution of fibrosis in the same treatment with MTX. The main target of MTX is the space of Disse [2] . Fibrogenesis in PS is frequently biopsy specimen. The high intra-and inter-observer reproducibility of SSS has been demonstrated in viral attributed to other drugs such as vitamin A, azathioprine or mercaptopurine [13] . Fibrosis is considered as a and alcoholic hepatitis [9] . SSS was also found to correlate well with the surface density of collagen measslower process that may be initiated by recurrent flares of necrosis, or may occur independently, in relation to ured by an image analysis system (morphometry) which is the gold standard assay of hepatic fibrosis [9] .
another stimulant [7] . Neither the Roenigk score nor the SSS demonstrated any progression of hepatic fibrosis SSS was found to be much more sensitive than the Roenigk score for the assessment of hepatic fibrosis in in patients having received 2 g of MTX, or showing abnormal levels of transaminases. Such stability has RA patients (x2 = 64, P < 0.005). The Roenigk score demonstrated a mild fibrosis in 33.8% of the specimens.
been reported and attributed to a tapering of NSAIDs, steroids and alcohol that often accompanies MTX By contrast, fibrosis was demonstrated by SSS in 94.5% of the same specimens and was graded as mild, moderate therapy [12] . However, such a reduction in other drug intake was not observed in this small group. The and even severe. The frequency of fibrosis was lower with the Roenigk score than with the SSS for two currently used sensitive method for fibrosis confirms the apparent lack of hepatotoxicity of long-term administrareasons. The Roenigk score is a composite five grade score measuring fatty infiltration, inflammation, nection of MTX in RA patients, the estimated risk of
